Compounders Research Compare

Quince Therapeutics, Inc.(QNCX)

Biotechnology · South San Francisco, CA

$27.04-1.06 (-3.77%)

Delayed quote: Oct 6, 2026, 1:45 PM EDT

About Quince Therapeutics, Inc.

Quince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases. A cornerstone of their innovation is an extensive bone-targeting drug delivery platform, engineered to accurately transport diverse therapeutic agents, such as small molecules, peptides, and large molecules, directly to affected bone areas like fractures and disease sites. Leading their pipeline is NOV004, an anabolic peptide meticulously designed to pinpoint and accumulate its therapeutic action precisely at bone fracture locations. The company, previously known as Cortexyme, Inc., officially rebranded as Quince Therapeutics, Inc. in August 2022. Established in 2012, Quince Therapeutics is headquartered in South San Francisco, California.

South San Francisco, CA

38 employees

www.quincetx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Dirk Thye

View full financials

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T17:47:55.266Z.

Stored calculation inputs

Calculation as of: 2026-10-06T17:47:55.266Z.

Quote observation: 2026-10-06T17:45:05.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 7,528,152
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 115,981,000
TTM free cash flow · period ending 2026-06-30: -47,001,000

FMP input reference: 2fc0b38e6dc372860fd9bea61ccff40ee6de978c8f50a2bbdf53c6942eb71849

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

QNCX EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

QNCX Competitors' EV/FCF Ratio

Quince Therapeutics, Inc.

Current

Market Cap

$7.53M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

InMed Pharmaceuticals Inc.

Market Cap

$7.27M

EV/FCF Ratio

N/A

TTM Avg

41004.37x

3Y Avg

41004.37x

5Y Avg

41004.37x

Skye Bioscience, Inc.

Market Cap

$7.26M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ENDRA Life Sciences Inc.

Market Cap

$7.80M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Longeveron Inc.

Market Cap

$7.21M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NeuroSense Therapeutics Ltd.

Market Cap

$7.18M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Traws Pharma, Inc.

Market Cap

$7.92M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Aprea Therapeutics, Inc.

Market Cap

$7.92M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Mangoceuticals, Inc.

Market Cap

$7.11M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

KALA BIO, Inc.

Market Cap

$7.07M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Quince Therapeutics, Inc. (QNCX)	$7.53M	N/A	N/A	N/A	N/A
InMed Pharmaceuticals Inc. (INM)vs ›	$7.27M	N/A	41004.37x	41004.37x	41004.37x
Skye Bioscience, Inc. (SKYE)vs ›	$7.26M	N/A	N/A	N/A	N/A
ENDRA Life Sciences Inc. (NDRA)vs ›	$7.80M	N/A	N/A	N/A	N/A
Longeveron Inc. (LGVN)vs ›	$7.21M	N/A	N/A	N/A	N/A
NeuroSense Therapeutics Ltd. (NRSN)vs ›	$7.18M	N/A	N/A	N/A	N/A
Traws Pharma, Inc. (TRAW)vs ›	$7.92M	N/A	N/A	N/A	N/A
Aprea Therapeutics, Inc. (APRE)vs ›	$7.92M	N/A	N/A	N/A	N/A
Mangoceuticals, Inc. (MGRX)vs ›	$7.11M	N/A	N/A	N/A	N/A
KALA BIO, Inc. (KALA)vs ›	$7.07M	N/A	N/A	N/A	N/A

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

Free Cash Flow FCF Yield P/FCF Ratio EV/EBITDA All Metrics